niharika times
  • National
  • Rajasthan
  • Sports
  • Cinema
  • Business
  • Recipe
No Result
View All Result
  • National
  • Rajasthan
  • Sports
  • Cinema
  • Business
  • Recipe
No Result
View All Result
niharika times
No Result
View All Result
Home Business

Rubicon Research Launches IPO with Subscription Period Ending October 13, 2025

by Tina TinaChouhan
October 9, 2025
Rubicon Research Launches IPO with Subscription Period Ending October 13, 2025

Pharmaceutical firm Rubicon Research has launched its IPO, which will remain open for three days until October 13, 2025. The company aims to raise funds for debt repayment and expansion. Key Details: Total Size: ₹1,377.5 crore Day 1 Subscription: 23% (38.24 lakh shares bid out of 1.64 crore) Non-Institutional Investors: 0.25 times subscribed Retail Investors: 0.90 times subscribed Anchor Investors: ₹619 crore raised (1.27 crore shares priced at ₹485 each) Price & Listing: Price Band: ₹461–485 per share Grey Market Premium: ₹80 (shares expected to list at ₹583) Allotment Date: October 14, 2025 Listing Date: October 16, 2025 on BSE and NSE Use of Funds: ₹310 crore for debt repayment with the remainder allocated for business growth and acquisitions.

ShareTweetSend

Related Posts

The Future of Humanoid Robots in Challenging Jobs

Reserve Your Favorite Jawa or Yezdi Motorcycle for Only Rs 999

Recent News

  • NDA Reveals Seat-Sharing Agreement for Bihar 2025 Elections
  • Teaser for ‘Vasudeva Sutham’ Released by Satya Dev
  • Raashi Khanna Teases Unique Take on Love in ‘TelusuKada’
  • Antony Varghese Reveals Intense New Look in ‘Kaattalan’
  • Taliban Minister Claims Exclusion of Women Journalists Was Unintentional
  • About Us
  • Contact Us
  • Cookie Policy
  • Corrections Policy
  • DMCA
  • Privacy & Policy
  • About
Call us: +91 97996 37175

© 2022 Niharika Times. All Rights Reserved

📰

  • National
  • Rajasthan
  • Sports
  • Cinema
  • Business
  • Recipe

© 2022 Niharika Times. All Rights Reserved

This website uses cookies. By continuing to use this website you are giving consent to cookies being used. Visit our Privacy and Cookie Policy.
Exit mobile version